PARP inhibitors and stratified treatment of prostate cancer

被引：5
|
作者：
Lavery, Anita [1 ]
Gilson, Clare [2 ]
Chowdhury, Simon [3 ]
机构：
[1] Guys Hosp, Med Oncol, London, England
[2] UCL, MRC Clin Trials Unit, London, England
[3] Guys Hosp, London, England
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2016年 / 16卷 / 12期
关键词：
Biomarker; BRCA1/2; mutation; PARP inhibitor; prostate cancer; stratification; targeted therapy; HOMOLOGOUS RECOMBINATION; INCREASED SURVIVAL; REPAIR DEFECTS; RESISTANCE; BIOMARKERS; BRCA2;
D O I：
10.1080/14737140.2016.1243474
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1213 / 1215
页数：3
相关论文
共 50 条
  • [41] PARP inhibitors as precision medicine for cancer treatment
    Yi Du
    Hirohito Yamaguchi
    Jennifer L.Hsu
    Mien-Chie Hung
    [J]. National Science Review, 2017, 4 (04) : 576 - 592
  • [42] PARP inhibitors for targeted treatment in ovarian cancer
    Dizon, Don S.
    [J]. LANCET, 2017, 390 (10106): : 1929 - 1930
  • [43] An Overview of PARP Inhibitors for the Treatment of Breast Cancer
    Cortesi, Laura
    Rugo, Hope S.
    Jackisch, Christian
    [J]. TARGETED ONCOLOGY, 2021, 16 (03) : 255 - 282
  • [44] PARP inhibitors for the treatment and prevention of breast cancer
    Vinayak S.
    Ford J.M.
    [J]. Current Breast Cancer Reports, 2010, 2 (4) : 190 - 197
  • [45] An Overview of PARP Inhibitors for the Treatment of Breast Cancer
    Laura Cortesi
    Hope S. Rugo
    Christian Jackisch
    [J]. Targeted Oncology, 2021, 16 : 255 - 282
  • [46] PARP Inhibitors in Prostate Cancer: Practical Guidance for Busy Clinicians
    VanderWeele, David J.
    Hussain, Maha
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (12) : 808 - 815
  • [47] Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors
    Maiorano, Brigida Anna
    Conteduca, Vincenza
    Catalano, Martina
    Antonuzzo, Lorenzo
    Maiello, Evaristo
    De Giorgi, Ugo
    Roviello, Giandomenico
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 192
  • [48] Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
    Neeb, Antje
    Herranz, Nicolas
    Arce-Gallego, Sara
    Miranda, Susana
    Buroni, Lorenzo
    Yuan, Wei
    Athie, Alejandro
    Casals, Teresa
    Carmichael, Juliet
    Nava Rodrigues, Daniel
    Gurel, Bora
    Rescigno, Pasquale
    Rekowski, Jan
    Welti, Jon
    Riisnaes, Ruth
    Gil, Veronica
    Ning, Jian
    Wagner, Verena
    Casanova-Salas, Irene
    Cordoba, Sarai
    Castro, Natalia
    Fenor de la Maza, Maria Dolores
    Seed, George
    Chandran, Khobe
    Ferreira, Ana
    Figueiredo, Ines
    Bertan, Claudia
    Bianchini, Diletta
    Aversa, Caterina
    Paschalis, Alec
    Gonzalez, Macarena
    Morales-Barrera, Rafael
    Suarez, Cristina
    Carles, Joan
    Swain, Amanda
    Sharp, Adam
    Gil, Jesus
    Serra, Violeta
    Lord, Christopher
    Carreira, Suzanne
    Mateo, Joaquin
    de Bono, Johann S.
    [J]. EUROPEAN UROLOGY, 2021, 79 (02) : 200 - 211
  • [49] PARP inhibitors in prostate cancer: time to narrow patient selection?
    Markowski, Mark C.
    Antonarakis, Emmanuel S.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (07) : 523 - 526
  • [50] PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers
    Mateo, Joaquin
    Carreira, Suzanne
    de Bono, Johann S.
    [J]. EUROPEAN UROLOGY, 2019, 76 (04) : 459 - 460
12345